Background : Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer. Therefore, we evaluated the efficacy and safety of irinotecan, 5-FU and a low dose of LV (modified FOLFIRI) as a first line of therapy for patients with relapsed or metastatic colorectal cancer. Results : The overall response rate was 47.8%. Of the 40 evaluated patients, one had CR (2.3%) and 20 had PR (46.5%). Toxicities were mild and easily manageable. Three patients experienced 23 episodes of Grade 3/4 leukopenia., Only one patient developed Grade 3/4 diarrhea. None experienced Grade 3/4 thrombocytopenia.
INTRODUCTION
Over the past 40 years, 5-fluorouracil (5-FU) and leucovorin (LV) have been the mainstays of chemotherapy drugs for advanced colorectal cancer. Recently, the combination of two new drugs, irinotecan or oxaliplatin, combined with 5-FU and LV, have demonstrated modest activity and improved survival as a first or second line of treatment. Irinotecan (CPT-11), a topoisomerase I inhibitor, was initially shown to have activity as a second line of therapy in patients with 5-FU resistant disease 1) . In recent phase III clinical trials, irinotecan plus a 5-FU/LV regimen improved both response and survival rates when compared with the control arm 2, 3) . However, the schedule and dose of irinotecan and 5-FU/LV have been fully modified in many trials, and an optimal protocol has not yet been determined.
As a third line of therapy for patients with metastatic colorectal cancer, a simplified bimonthly schedule of irinotecan with a high dose of 5-FU LV (FOLFIRI regimen) showed both activity and an acceptable level of toxicity in heavily treated patients 4) . As a first line of treatment, this regimen showed 31～ 56% response rates, without serious toxicity [5] [6] [7] .
In determining the optimal dose of 5-FU and LV, it was found that a high dose of 5-FU delivered a better response rate and longer response duration than a low dose of 5-FU. On the other hand, a low dose of LV was as effective and produced similar toxicities as a high dose of LV in combination with 5-FU. These results indicated that, when in combination with 5-FU, a low dose of LV is as effective as a high dose in the palliative management of patients with metastatic colorectal cancer 8) .
In the present study, we retrospectively evaluated the efficacy and safety of irinotecan, 5-FU and a low dose of LV (modified FOLFIRI regimen) every two weeks in relapsed or metastatic colorectal cancer.
MATERIALS AND METHODS

Patients
Patients included in the study were required to be 18～75 years old with a confirmed histologically, metastatic or recurrent colorectal cancer, and who had not received any prior chemotherapy. Adjuvant treatment, if administered, should have been completed at least six months before being enrolled. Other inclusion criteria were as follows: (i) a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG); (ii) a bi-dimensionally measurable lesion, with a metastatic lesion or lymphadenopathy greater than 10 mm; (iii) an adequate bone marrow reserve (WBC count >4,000/μL, platelet count >100,000/μL); and (iv) a normal cardiac function. (v) normal renal function (serum creatinine <1.5 times the upper normal limit (UNL)); (vi) an adequate hepatic function (AST and ALT <2.5 times UNL and total bilirubin <1.5 times UNL; patients with obstructive jaundice should have undertaken internal or external biliary drainage before enrollment); and (vii) an estimated life expectancy of at least 12 weeks at the time of enrollment. All approved patients or legal representatives signed informed consent forms before treatment began. 
Dose modification
Prior to each treatment, we recorded the patient's history and performed physical examinations, CBC (complete blood counts), blood chemistry, and conducted a urine analysis. If the absolute neutrophil count was less than 1,500/μL or the platelet count was less than 100,000/μL, treatment was delayed for one week or until myelosuppression was resolved. If a patient was not fully recovered after seven days, the dose was reduced by 25%. If Grade 3/4 non-hematologic toxicity developed, the dose was decreased by 25%. If there was a second episode of Grade 3/4 non-hematologic toxicity, treatment was stopped.
Assessment of response and toxicity Physical examinations, peripheral blood count, blood chemistry, and chest X-ray were performed during each patient visit. CT scans were performed at the baseline and after four treatment courses. Response to treatment was assessed according to World Health Organization (WHO) criteria. Before each cycle, patients were assessed for toxicity according to the National Cancer Institute common toxicity criteria Statistics Time to progression (TTP) was defined from the first day of chemotherapy to the day of confirmed progression. Overall survival (OS) was calculated from the first day of chemotherapy to death or final follow-up. All data were analyzed using the Kaplan-Meier method using the SPSS program (version 11.0). of cycles was six (range, 1-16). The overall response rate was 47.8% (95% Confidence interval; 32.5～63.2%) ( Table 2) . Of the 44 patients, one had CR (2.3%), while 20 had PR (45.5%). Of the 40 evaluated patients, the response rate was 52.5% (95% Confidence interval; 37.2～67.8%). There was no significant difference in response rates associated with previous chemotherapy history (Table 3 ) (p=0.054). The median follow-up for surviving patients was 53 weeks (23-121 weeks). The median time to progression was 23 weeks (7-57 weeks) while median survival was 47 weeks (18-121 weeks) (Figure 1 ). Toxicity A total of 288 cycles for 44 patients were evaluated for toxicity, and the toxicity incidence is summarized in Table 4 . One patient required a 25% dose reduction due to delayed bone marrow suppression, and two patients required a delay of treatment for one week due to non-recovery from bone marrow suppression. Three patients experienced a total of 23 episodes of Grade 3/4 leukopenia, but no Grade 3/4 thrombocytopenia was observed (Table 4) . Two patients experienced Grade 3/4 neutropenic infections without septic shock. No treatmentrelated deaths occurred.
RESULTS
Clinical characteristics
The most common non-hematologic toxicities were diarrhea, nausea and vomiting. But only one patient developed Grade 3/4 diarrhea, and one patient developed Grade 3 vomiting. Three episodes of Grade 4 mucositis were observed in one patient. No treatment-related deaths occurred during any of the chemotherapy cycles.
DISCUSSION
FOLFIRI, (a combination of irinotecan, 5-FU and LV), has been recommended as a standard treatment for advanced colorectal cancer, having shown response rates of 39.8～56% as a first line of treatment 2, 3, 5) . However, a clinical trial using this regimen in Germany, subsequently showed a response rate of only 31%, which may have been due to a higher percentage of patients with two or more metastatic sites, and hence a larger tumor 6) . The poorer outcome in this trial may have been due to the inclusion of a greater percentage of patients with rectal cancer (34%), or to the enrollment of patients previously treated with 5-FU and LV (14%). In our trial, using a modified FOLFIRI regimen, 45.5% of the patients had rectal cancer and 43% had previous treatment with 5-FU chemotherapy regimen. . Using 150 mg/m 2 of irinotecan and a low dose of LV (20 mg/m 2 ) in patients with metastatic colorectal cancer as a second line of treatment, the response and median survival rates were lower (20% and 39.6 weeks), respectively 10) . This lower response rate may have been due to the use of this chemotherapy regimen as a second line of treatment or to the lower dose of irinotecan. However, a lower response rate (27.3%) was observed in patients with metastatic colorectal cancer using a regimen identical to ours, but with fewer treatment cycles 11) . Although we found that FOLFIRI with a low dose of LV, achieved a response rate comparable to that of the previous study (47.8% vs. 40%), the median overall survival time was somewhat shorter (11 months vs. 17-21 months). This may well have been due to the shorter follow-up period for surviving patients (median 13.3 months), suggesting that the median overall survival time should be reevaluated after a long-term follow-up.
The most common toxicities associated with irinotecan are neutropenia, anemia, delayed diarrhea, and fatigue. Since irinotecan was initially associated with high death rates 12) , its use has been modified to exclude patients who have a performance status 2 -at high risk for adverse events. In fact, Grade 3/4 gastrointestinal even, especially diarrhea, was the most common serious problem with an incidence of 22～45% [13] [14] [15] [16] . Thus, the monitoring of patients for gastrointestinal (e.g. diarrhea, nausea, abdominal cramping) and thromboembolic events during treatment is essential. If fever associated with neutropenia develops, prompt supportive care, including early use of oral fluoroquinolone, are needed 17) . However, in our study, incidence of Grade 3/4 delayed diarrhea was only 1.7%. We had instructed all patients in this trial to take anti-diarrhea agents if they had diarrhea more than five times a day (but almost patients did not take medication). In other trials of irinotecan in South Korea, Grade 3/4 delayed diarrhea was not common, having an incidence of 1.2～ 6.7% [9] [10] [11] , unlike in Western countries. We suggest that this may be due to ethnic differences, although we could not determine whether any medications to prevent delayed diarrhea were administered in the other South Korean clinical trials. We found that other non-hematologic toxicities were manageable and reversible, and overall, patients tolerated this regimen.
In summary, irinotecan, 5-FU and a low dose of LV may be as effective as irinotecan, 5-FU and a high dose of LV, and considerably tolerable for patients with recurrent or metastatic colorectal cancer as a first line of treatment.
